Development and validation of a UV-spectrophotometric method for the determination of pheniramine maleate and its stability studies
- 111 Downloads
A sensitive, precise, and cost-effective UV-spectrophotometric method is described for the determination of pheniramine maleate (PAM) in bulk drug and tablets. The method is based on the measurement of absorbance of a PAM solution in 0.1 N HCl at 264 nm. As per the International Conference on Harmonization (ICH) guidelines, the method was validated for linearity, accuracy, precision, limits of detection (LOD) and quantification (LOQ), and robustness and ruggedness. A linear relationship between absorbance and concentration of PAM in the range of 2–40 μg/ml with a correlation coefficient (r) of 0.9998 was obtained. The LOD and LOQ values were found to be 0.18 and 0.39 μg/ml PAM, respectively. The precision of the method was satisfactory: the value of relative standard deviation (RSD) did not exceed 3.47%. The proposed method was applied successfully to the determination of PAM in tablets with good accuracy and precision. Percentages of the label claims ranged from 101.8 to 102.01% with the standard deviation (SD) from 0.64 to 0.72%. The accuracy of the method was further ascertained by recovery studies via a standard addition procedure. In addition, the forced degradation of PAM was conducted in accordance with the ICH guidelines. Acidic and basic hydrolysis, thermal stress, peroxide, and photolytic degradation were used to assess the stability-indicating power of the method. A substantial degradation was observed during oxidative and alkaline degradations. No degradation was observed under other stress conditions.
Keywordspheniramine maleate degradation spectrophotometry pharmaceuticals
Unable to display preview. Download preview PDF.
- 1.K. D. Thripathi, 2008 Histamine and Antihistamines in Essentials of Medical Pharmacology, Jaypee Brothers’ Medical Publishers, 6th ed., 155 (2008).Google Scholar
- 2.British Pharmacopoeia, the Stationary Office, London, Vol. I & II (2009).Google Scholar
- 3.United States Pharmacopoeia, 30, NF 25, 2917 (2007).Google Scholar
- 9.A. G. Ghanekar and V. D. Gupta. Am. J. Hosp. Phar., 34, 651 (1977).Google Scholar
- 11.S. K. Pant, B. K. Maitin, and C. L. Jain, Indian Drugs., 28, 105 (1990).Google Scholar
- 13.S. P. Subramaniyan and S. K. Das, J. AOAC Int., 87, 1319 (2004)Google Scholar
- 14.Y. Chang, C. Lee, T. Shyu, and C. Chuang, Chin. Electron. Period. Serv., 73 (1987).Google Scholar
- 15.H. L. Wu, C. H. Huang, S. H. Chen, and S. M. Wu, J. Chromatogr. Sci., 37 (1999).Google Scholar
- 17.K. Nikolic, R. Popovic, and M.Medenica, Arh. Farm., 29, 109 (1979).Google Scholar
- 21.ICH-Q1A, Stability Testing of New Drug Substances and Products, International Conference on Harmonisation, Geneva, February 2003.Google Scholar